Dr. Vinod Chaudhari received his PhD in Organic/Carbohydrate Chemistry from University of Pune and subsequently moved to University Joseph Furrier (CNRS), Grenoble, France for a Post-Doctoral training. He has over 20 years of drug discovery research experience from pharma industries and academia. He has worked at Lupin Limited, Aurigene Discovery, and Zydus-Cadila, prior to joining CSIR-IMTECH Jan 2019. Vinod has experience in leading drug discovery teams from concept to clinic, that successfully delivered several preclinical/clinical drug candidates. He has experience in working with various drug target classes including GPCRs, Ion channels and Kinases, across different therapeutic areas like Metabolic disorders, Oncology, Respiratory diseases, Inflammation, and Neurosciences.

At CSIR-IMTECH his major focus is on new drug discovery in the different therapeutic areas like of Antimicrobial resistance, Infectious and Neglected diseases. Currently his research group is working on design and synthesis of novel small molecules inhibitors targeting for the therapeutic area of Respiratory infectious diseases particularly Antimicrobial resistance (AMR), Tuberculosis (TB), and Viral diseases. His research also focuses on total synthesis of biologically active natural/unnatural products and development of novel synthetic methodologies.

• Disarming superbugs: New frontiers in inhibiting NDM-1 and other clinically relevant metallo-β-lactamases. Dhiman, et al; European Journal of Medicinal Chemistry, 2026, 301, 118220.
• Discovery of Conformationally Constrained Dihydro Benzo-Indole Derivatives as Pan-Metallo-β-Lactamase Inhibitors to Tackle Multidrug-Resistant Bacterial Infections; Dhiman, et al; Journal of Medicinal Chemistry, 2025, 68 (7), 7062.
• Palladium-Catalyzed Intramolecular C−H Amination via Oxidative Coupling on Indole Derivatives: Access to 11H‑Benzo[4,5]imidazo[1,2‑a]indoles; Sharma, Y., et al. Organic Letters, 2025, 27, 517
• Synthesis of Triazolo[4′,5′:4,5]furo[2,3-c]pyridine via Post Modification of an Unusual Groebke–Blackburn–Bienaymé Multicomponent Reaction; Batra, et al; ACS Omega, 2024, 9, 27, 29372.
• Diversity in the ligand binding pocket of HapR attributes to its uniqueness towards several inhibitors with respect to other homologues-A structural and molecular perspective. Sen et al; International Journal of Biological Macromolecules, 2023, 233, 12395.
• One-Pot Domino Reaction: Direct Access to Polysubstituted 1,4- 2 Benzothiazine 1,1-Dioxide via Water-Gas Shift Reaction Utilizing DMF/H2O; Sharma et al. The Journal of Organic Chemistry, 2023, 88 (1), 701.
• Discovery of LNP1892: A Precision Calcimimetic for the Treatment of Secondary Hyperparathyroidism; Shukla, M. R., et al; ACS - Journal of Medicinal Chemistry, 2023, 66, 14, 9418
• Discovery of a Potent and Selective PI3Kδ Inhibitor (S)-2,4-Diamino-6-((1-(7-fluoro-1-(4-fluorophenyl)-4-oxo-3-phenyl-4H-quinolizin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile with Improved Pharmacokinetic Profile and Superior Efficacy in Hematological Cancer Models. Shukla, M. R., et al.; Journal of Medicinal Chemistry, 2020, 63 (23), 14700.
• Identification of a Novel Series of Orexin Receptor Antagonists with a Distinct Effect on Sleep Architecture for the Treatment of Insomnia. Betschart C., et al; Journal of Medicinal Chemistry, 2013, 56 (19), 7590
• An Efficient Synthesis of D-erythro- and D-threo-Sphingosine from D-Glucose: Olefin Cross-Metathesis Approach. Chaudhari, V. D., et. al.; Organic Letters, 2005, 7, 5805.

• Dihydrochromeno-Pyrrole Compounds as Metallo-Beta-Lactamase Inhibitors and Process for The Preparation Thereof; IN2023/11041398, WO2024/257126.
• Small Molecule for the Treatment of Mycobacterial Diseases; IN2023/11007303, WO2024/161423A1.
• Compounds for treating Viral Infections; IN2023/11007365
• Substituted Benzimidazole for Treating Viral Diseases; IN2022/11044091, WO2024/028893, EP23849660.
• Substituted Tricyclic Heterocyclic Compounds as Metallo-beta-Lactamase Inhibitors. IN2021/11024755, WO2022/254464A1, US2024/0279176, JP2024/520130A, BR112023/025328A2, EP4347595A1.
• Arylalkylamine Compounds as Calcium Sensing Receptor Modulators. WO2014/033604, US2015/239827, US2016/075655, US2017/0137371, EP2888225, AU2013/308081, CA2882039, CN104583177, IN421MUN2015, JP2015/528462, HK1211916.
• Substituted Morpholines as Modulators for The Calcium Sensing Receptor. WO2012/120476, US2013/345213, US2016/0250219, EP2683697, AU2012/226375, CA2828415, ZA2013/06576, IN2011KOL31720110310.
• Diaza-spiro[5,5]undecanes as Orexin Receptor Antagonists; WO2011/076747, US2012/2264748, EP2516439, JP2013/515033, AR079553, CN102762567, TW2011/32642, UY33125; Novartis AG, Switzerland.
• Disubstituted Heteroaryl-Fused Pyridines. WO2011/076744, US2012/258973, EP251637, CN102762560, IN2009/02664, JP2013/515032.
• Di/tri-Aza-Spiro-C9-C11 Alkanes. WO2012/101487, US2012/165331, AR084430.